Seek Returns

RGEN vs. ROIV: Repligen vs. Roivant Sciences Stock Comparison

How do Repligen (RGEN) and Roivant Sciences (ROIV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Repligen (RGEN) and Roivant Sciences (ROIV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RGEN is classified in Life Sciences Tools & Services while ROIV is classified in Biotechnology.

Repligen (RGEN) has more than two decades of public-market history since April 29, 1986, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.

Company profile comparison for Repligen (RGEN) and Roivant Sciences (ROIV)
Profile ItemRGENROIV
NameRepligen CorporationRoivant Sciences Ltd.
Country/RegionUnited StatesUnited Kingdom
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization11.09 billion USD28.08 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateApril 29, 1986December 8, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

RGEN
ROIV
GSPC
Loading price history…
Repligen (RGEN) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Repligen (RGEN) and Roivant Sciences (ROIV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Repligen (RGEN) and Roivant Sciences (ROIV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Repligen (RGEN) and Roivant Sciences (ROIV)
MetricRGENROIV
Total Return (1Y)23.28%96.75%
Total Return (3Y, Annualized)6.20%68.04%
Total Return (5Y, Annualized)-8.41%36.73%

Risk Profile

Drawdown History

RGEN
ROIV
GSPC
Loading price history…
Repligen (RGEN) vs. Roivant Sciences (ROIV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Repligen (RGEN) and Roivant Sciences (ROIV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Repligen (RGEN) and Roivant Sciences (ROIV)
MetricRGENROIV
Volatility (1Y, Annualized)46.73%47.99%
Beta (5Y)1.111.17
Max Drawdown (5Y)-64.67%-79.22%
Avg. Volume (3M)1.18M7.82M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RGEN and ROIV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Repligen (RGEN) and Roivant Sciences (ROIV)
MetricRGENROIV
Sharpe Ratio (1Y)0.411.93
Sortino Ratio (1Y)0.604.03

Profitability

ROE (TTM)

Both Repligen (RGEN) at -0.57% and Roivant Sciences (ROIV) at -8.52% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.57%

Max
109.18%
Q3
6.23%
RGEN
-0.57%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.52%

Max
109.18%
Q3
6.23%
ROIV
-8.52%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile Roivant Sciences (ROIV) reports 0.00%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-1.47%

Max
18.05%
Q3
4.78%
Median
0.00%
RGEN
-1.47%
Q1
-4.14%
Min
-17.05%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
ROIV
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Repligen (RGEN) reports 6.19%, ranking against industry peers normally.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.19%

Max
83.12%
Q3
14.77%
RGEN
6.19%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-25,408.11%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
ROIV
-25,408.11%
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Repligen (RGEN) and Roivant Sciences (ROIV)
MetricRGENROIV
ROE (TTM)-0.57%-8.52%
ROA (TTM)1.40%-16.28%
Net Margin (TTM)-1.47%0.00%
Operating Margin (TTM)6.19%-25,408.11%
Gross Margin (TTM)53.77%0.00%

Growth

Revenue Growth

Repligen (RGEN) at 16.36% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither Repligen (RGEN) nor Roivant Sciences (ROIV) reports a EPS growth value for this period, so a direct comparison isn't possible.

Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Repligen (RGEN) and Roivant Sciences (ROIV)
MetricRGENROIV
Revenue Growth (YoY)16.36%-71.57%
Revenue Growth (3Y CAGR)-2.70%-36.01%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)-35.73%--

Financial Strength

Current Ratio (MRQ)

Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while Roivant Sciences (ROIV) at 16.72 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.88

Max
25.13
Q3
12.13
RGEN
9.88
Median
5.52
Q1
2.47
Min
0.10

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.72

Max
25.13
ROIV
16.72
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Repligen (RGEN) at 0.33 and Roivant Sciences (ROIV) at 0.02 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.33

Max
1.42
Q3
0.65
RGEN
0.33
Median
0.15
Q1
0.02
Min
0.00

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max
1.42
Q3
0.65
Median
0.15
ROIV
0.02
Q1
0.02
Min
0.00
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Repligen (RGEN) and Roivant Sciences (ROIV)
MetricRGENROIV
Current Ratio (MRQ)9.8816.72
Debt / Equity (MRQ)0.330.02
Net Debt / EBITDA-1.19--

Dividends

Dividend Yield (TTM)

Neither Repligen (RGEN) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Repligen (RGEN) nor Roivant Sciences (ROIV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

RGEN
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ROIV
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Repligen (RGEN) and Roivant Sciences (ROIV)
MetricRGENROIV
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither Repligen (RGEN) nor Roivant Sciences (ROIV) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
RGEN
--

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
ROIV
--
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

Repligen (RGEN) at 13.77 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.77

Max
58.18
Q3
25.77
RGEN
13.77
Median
7.30
Q1
3.01
Min
0.01

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

3,728.61

ROIV
3,728.61
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Repligen (RGEN) at 4.70 is valued about in line with its industry on P/B ratio, while Roivant Sciences (ROIV) at 6.64 carries an above-peer premium to book — ROIV is pricier on assets.

RGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70

Max
13.53
Q3
6.54
RGEN
4.70
Median
3.25
Q1
1.69
Min
-5.59

ROIV

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.64

Max
13.53
ROIV
6.64
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Repligen (RGEN) vs. Roivant Sciences (ROIV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Repligen (RGEN) and Roivant Sciences (ROIV)
MetricRGENROIV
P/E Ratio (TTM)----
P/S Ratio (TTM)13.773,728.61
P/B Ratio (MRQ)4.706.64
Free Cash Flow Yield (TTM)1.01%-3.98%